Clinical Trial: The Safety and Efficacy of Roflumilast Foam in HS

U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07263230) titled 'The Safety and Efficacy of Roflumilast Foam in HS' on Nov. 24.

Brief Summary: This study investigates the efficacy of topical roflumilast foam in patients with HS.

Study Start Date: April 01, 2026

Study Type: INTERVENTIONAL

Condition: Hidradenitis Suppurativa (HS)

Intervention: DRUG: Roflumilast 0.3% topical foam

Roflumilast foam, 0.3%, is a phosphodiesterase 4 inhibitor

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Beth Israel Deaconess Medical Center

Information provided by (Responsible Party): Martina Porter, Beth Israel Deaconess Medical Center

Disclaimer: Curated by HT Syndication....